Abstract
In the recent years, many monoclonal antibody drugs related to the immunotherapy is taken by many cancer patients. This passage will give the information about the three common checkpoint inhibitor drugs. Information of each of drug will be divide into three parts including mechanism and structure, efficiency and strength, drawback and side-effect. Then limitation and new improvement of checkpoint inhibitor drugs of all three drugs will be introduced in the last part.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
